Navigation Links
Abbott Successfully Completes Tender Offer for Shares of Advanced Medical Optics
Date:2/25/2009

ABBOTT PARK, Ill., Feb. 25 /PRNewswire-FirstCall/ -- Abbott today announced the successful completion of the tender offer by its wholly owned subsidiary Rainforest Acquisition Inc. to purchase all of the outstanding shares of common stock of Advanced Medical Optics (AMO). The tender offer expired at midnight Eastern time on Tuesday, Feb. 24, 2009, and was not extended.

The depositary for the tender offer has advised Abbott that a total of approximately 56,395,914 shares of AMO common stock were validly tendered and not withdrawn (including approximately 6,657,258 shares subject to guaranteed delivery procedures). These shares, together with the shares beneficially owned by Abbott and its wholly owned subsidiaries, represent approximately 93.5 percent of AMO's outstanding shares of common stock, or approximately 83.1 percent on a fully diluted basis. All AMO shares that were validly tendered in the offer and not properly withdrawn have been accepted for payment.

As the final step of the acquisition process, Abbott intends to effect a short-form merger as promptly as practicable, without the need for a meeting of AMO stockholders. As a result of the merger, the remaining AMO stockholders (other than those who properly exercise dissenters' rights) will receive the same $22 per share price, without interest and subject to any required withholding taxes, that was paid in the tender offer. After the merger, AMO will be a wholly owned subsidiary of Abbott and AMO shares will cease to be traded on the New York Stock Exchange.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs approximately 69,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at www.abbott.com.

-- Private Securities Litigation Reform Act of 1995 --

A Caution Concerning Forward-Looking Statements

Some statements in this news release may be forward-looking statements for the purposes of the Private Securities Litigation Reform Act of 1995. We caution that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors," to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended Dec. 31, 2008, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments.


'/>"/>
SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Abbott Receives European Commission Clearance on Acquisition of Advanced Medical Optics
2. Abbott Receives FDA Clearance for New CELL-DYN(R) Emerald(TM) Hematology Instrument
3. Abbott Acquisition of Advanced Medical Optics Clears U.S. Antitrust Review
4. Fujirebio Diagnostics and Abbott Agree To Develop New Ovarian Cancer Test for Abbotts Architect(R) Analyzers
5. Abbott to Commence Tender Offer on Jan. 27 for All Outstanding Shares of Advanced Medical Optics, Inc.
6. Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Confirms Strong Outlook for 2009 Earnings
7. Abbott Opens New Pharmaceutical Research Laboratory in Singapore
8. Abbott Nutrition Announces Voluntary Recall of ZonePerfect(R) Chocolate Peanut Butter Bars, ZonePerfect(R) Peanut Toffee Bars and NutriPals(TM) Peanut Butter Chocolate Bars in U.S., Mexico, New Zealand and Singapore
9. Abbott Receives FDA CLIA Waiver for Use of Five Additional Cartridges on the i-STAT Handheld Blood Analyzer
10. Rubicon Genomics Announces a Licensing Agreement With Abbott to Develop and Commercialize DNA Methylation Cancer Tests
11. Halo Pharmaceutical, Inc. Acquires Whippany Manufacturing Facility from Abbott
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... , ... March 29, 2017 , ... Curio Wellness ... to announce the finalization of the company’s executive management team with prominent executives from ... operations is Curio Wellness’ Chief Operating Officer, Ted Dumbauld , who has more ...
(Date:3/29/2017)... ... March 29, 2017 , ... HealthCareMandA.com will host an ... 20, 2017, at 1:00 PM ET. A recording of the webinar will also be ... Series. , Home health and hospice companies are still popular targets for healthcare investors. ...
(Date:3/29/2017)... ... ... Immunotherapy has emerged as one of the most promising options for the ... next revolution in our fight against this complex disease. One of the most effective ... such as PD-1 and PD-L1 inhibitors. , While a few single analyte immunohistochemistry tests ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... of Pittsburgh now have easier access to the robotic-assisted total-hip and partial-knee ... Network (AHN). Orthopaedic surgeons at Forbes Hospital and Jefferson Hospital recently started ...
(Date:3/29/2017)... ... March 29, 2017 , ... The Wharton School of the ... Taffet Moelis, W’81, have made a $10 million gift to establish the Ken ... will provide a pathway to a Wharton MBA for highly-qualified Penn undergraduates whose academic ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... DUBLIN , Mar. 29, 2017 ... "Intraoperative Neuromonitoring (IONM) Market Size & Forecast By Type (Insource ... - 2025" report to their offering. ... The global Intraoperative ... by 2025. The intraoperative neuromonitoring market is anticipated to witness ...
(Date:3/29/2017)... March 29, 2017 Global intravenous (IV) iron and ... by 2021, growing at a CAGR of 5%. ... a doctor to treat anemia or other iron deficiencies. Oral ... the body. However, in some cases, oral administrations are not ... intravenous (IV) iron therapy comes into the picture. ...
(Date:3/29/2017)... 29, 2017 Today, CVS Health officials (NYSE: ... , Department of Public Health Director Gerd Clabaugh ... in announcing the availability of the opioid overdose-reversal medicine ... Iowa.  CVS Health has established a standing order with physicians ... to expand access to the medication in the state.   ...
Breaking Medicine Technology: